Drugs / TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft
TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04806347 | Jul 2026 → May 2029 expected | hematologic disorder | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCRαβ+/CD19+ depleted Hematopoietic stem cell (HSC) graft | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04806347 ↗ |
| Modality | Cell therapy | “peripheral blood stem cell transplant” NCT04806347 ↗ |
| Route | Intravenous | “will be administered intravenously on Day 0” NCT04806347 ↗ |